AbstractBackgroundDown syndrome (DS), the most common chromosomal disorder that is a genetic cause of intellectual disability (ID), is characterized by mild‐to‐severe cognitive deficits and several neurological and brain anatomical abnormalities in people with DS and in animal models of DS. Among them, a marked reduction in the volume of the cerebellum has been reported in fetuses, newborns, and adults with DS, and in mouse models of DS. It has been well documented that children and adults with DS display motor deficits consistent with cerebellar abnormalities. Growing evidence suggests that the cerebellum is involved in the processing of cognitive functions. Reduced size of the cerebellum may be one of the underlying causes of cognitive deficits in DS. However, the cellular functions of the cerebellum remain poorly understood in people with DS. The beneficial effects of treatment with the hematopoietic growth factor granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) in animal models of DS, Alzheimer’s disease (AD), normal aging, and clinical trials of AD subjects suggest that it may serve as a potential therapeutic for these disorders. Our recent published data showed that treatment with GM‐CSF rescues the cognitive impairments and improves hippocampal pathology in Dp16 mice. To elucidate cerebellum‐associated cellular functions, we investigated purkinje cell pathology in aged male Dp16 mice after treatment with GM‐CSF compared to saline‐injected mice.MethodWe injected 12‐ to 14‐month‐old male Dp16 male mice subcutaneously with GM‐CSF (5 mg/day; 5 days/week) or with saline (200 ml) for 24 injections total over 29 days. On day 29, the brains were fixed, and tissues were processed for immunohistochemistry.ResultWe observed a reduced number of parvalbumin‐positive purkinje cells and loss of arborization in the cerebellum of male Dp16 mice compared to wild‐type littermates. Treatment with GM‐CSF significantly increased the number of parvalbumin‐positive purkinje cells and partially restored dendritic arborization in the cerebellum of Dp16 mice compared to saline‐injected mice.ConclusionOur results suggest that treatment with GM‐CSF improves cellular abnormalities by increasing the number of purkinje cells in the cerebellum of Dp16 mice. Taken together with our previous results, these findings provide further evidence that GM‐CSF/sargramostim may have therapeutic benefits in people with DS.